Compare · HAYW vs TMO
HAYW vs TMO
Side-by-side comparison of Hayward Holdings Inc. (HAYW) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAYW and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $222.03B, about 76.9x HAYW ($2.89B).
- Over the past year, HAYW is down 13.7% and TMO is up 23.3% - TMO leads by 37.0 points.
- TMO has been more active in the news (16 items in the past 4 weeks vs 4 for HAYW).
- TMO has more recent analyst coverage (25 ratings vs 21 for HAYW).
- Company
- Hayward Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $13.62-3.17%
- $600.37-2.82%
- Market cap
- $2.89B
- $222.03B
- 1M return
- -12.10%
- +4.60%
- 1Y return
- -13.67%
- +23.30%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 16
- Recent ratings
- 21
- 25
Hayward Holdings Inc.
Hayward Holdings, Inc. operates as a designer, manufacturer, and marketer of various pool equipment and associated automation systems. The company offers a range of pool equipment, including pumps, filters, heaters, automatic cleaners, sanitizers, controls, and LED lights, as well as industrial thermoplastic valves and process liquid control products for in-ground residential pools, above ground pools, and commercial pools. Hayward Holdings, Inc. is based in Berkeley Heights, New Jersey.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest HAYW
- New insider Lino Juliana Izabel claimed ownership of 12,362 shares (SEC Form 3)
- Amendment: SVP, CLO, Corporate Secretary Canning Susan M. sold $52,710 worth of shares (3,500 units at $15.06), decreasing direct ownership by 2% to 171,411 units (SEC Form 4)
- SVP, CLO, Corporate Secretary Canning Susan M. sold $52,500 worth of shares (3,500 units at $15.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,411 units (SEC Form 4)
- SEC Form 144 filed by Hayward Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Hayward Holdings Inc.
- SEC Form SCHEDULE 13G filed by Hayward Holdings Inc.
- VP&GM, Europe & Rest of World Ramirez Dario Vicario covered exercise/tax liability with 598 shares, decreasing direct ownership by 5% to 11,570 units (SEC Form 4) to satisfy withholding obligation
- VP, Chief Engineering Officer Gallagher Kevin covered exercise/tax liability with 1,132 shares, decreasing direct ownership by 3% to 35,924 units (SEC Form 4) (for tax liability)
- SVP, Chief Human Resources Lewis Raymond H Jr covered exercise/tax liability with 1,236 shares, decreasing direct ownership by 3% to 45,970 units (SEC Form 4) to cover withholding tax
- President and CEO Holleran Kevin exercised 50,000 shares at a strike of $1.40 and sold $765,690 worth of shares (50,000 units at $15.31) as part of a pre-agreed trading plan (SEC Form 4)
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)